6618.HK stock is trading at HKD 51.95, down 8.46% in pre-market trade on 04 Mar 2026 as investors position ahead of JD Health’s earnings due 05 Mar 2026. The move follows heavy volume of 11,046,244 shares and reflects short-term profit taking against a one-year gain of 51.55%. The upcoming report will be the first major catalyst this week and could redefine near-term valuation given a trailing PE of 31.83 and EPS of HKD 1.69.

Earnings catalyst: 6618.HK stock

JD Health (6618.HK) reports earnings on 05 Mar 2026, and expectations centre on margin recovery and services monetisation. Street focus will be revenue mix between pharmacy sales and online medical services, plus guidance for 2026. A stronger-than-expected margin beat would likely push shares above nearby resistance at HKD 53.80.

Valuation and fundamentals: 6618.HK stock analysis

The company trades at PE 31.83 with EPS HKD 1.69 and market cap about HKD 172.24B. Balance-sheet strength is clear: cash per share HKD 14.02, current ratio 2.92, and negligible net debt. Price to sales is 2.33 and PB is 2.62, leaving valuation rich versus some healthcare peers but supported by 2024 net income growth of 94.31%.

Technical view and trading signals: 6618.HK stock

Technicals show short-term weakness: RSI 30.51 and MACD negative. The stock is below its 50-day average (HKD 61.19) and 200-day average (HKD 57.06). Day range sits at HKD 51.50–53.80 and the stock is oversold on several oscillators, suggesting a possible bounce if earnings meet or beat estimates.

Meyka grade and forecast: 6618.HK stock model

Meyka AI rates 6618.HK with a score out of 100: 76.96 — Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly target of HKD 77.72, implying ~49.60% upside from the current HKD 51.95. Quarterly model target is HKD 75.96 (≈46.22% upside). Forecasts are model-based projections and not guarantees. For context and live news, see recent coverage on Investing.com and broader market moves on MarketWatch.

Catalysts, risks and sector context: 6618.HK stock outlook

Key catalysts include stronger services monetisation, margin expansion, and new B2B health services contracts. Main risks are slower pharmacy growth, regulatory changes in China, and a high valuation relative to sector averages. The Hong Kong healthcare sector is down 4.25% week-to-date, adding macro pressure on 6618.HK stock.

Final Thoughts

Short-term pressure on 6618.HK stock leaves an active trading setup ahead of JD Health’s earnings on 05 Mar 2026. Key metrics to watch in the report are revenue split, adjusted operating margin, and management guidance. Meyka AI’s model projects HKD 77.72 for the year, implying ~49.60% upside from HKD 51.95, while the quarterly target of HKD 75.96 implies ~46.22% upside. Technical indicators signal oversold conditions, which could produce a relief rally if results beat expectations. Conversely, any guidance cut would likely extend downside toward prior support near HKD 51.50 and the 200-day average at HKD 57.06. Investors should weigh valuation (PE 31.83) against strong cash per share (HKD 14.02) and recent net income growth. This analysis uses Meyka AI data and models for context; forecasts are projections and not guarantees, and this is not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.